Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

@article{Santoro2013TivantinibFS,
  title={Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.},
  author={Armando Santoro and Lorenza Rimassa and Ivan Borbath and Bruno Daniele and Stefania Salvagni and Jean Luc Van Laethem and Hans R Van Vlierberghe and Joerg Trojan and Frank Thomas Kolligs and Alan Weiss and Steven Miles and Antonio Gasbarrini and Monica Lencioni and Luca Cicalese and Morris Sherman and Cesare Gridelli and Peter Buggisch and Guido G H Gerken and Roland M Schmid and Corrado Boni and Nicola Personeni and Ziad M Hassoun and Giovanni Abbadessa and Brian Schwartz and Reinhard von Roemeling and Maria E. Lamar and Yinpu Chen and Camillo Porta},
  journal={The Lancet. Oncology},
  year={2013},
  volume={14 1},
  pages={55-63}
}
BACKGROUND Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma. METHODS In this completed, multicentre, randomised… CONTINUE READING